Menu
Search
|

Menu

Close
X

Affimed NV AFMD.OQ (NASDAQ Stock Exchange Global Market)

1.77 USD
+0.03 (+1.43%)
As of 2:59 PM EDT
chart
Previous Close 1.75
Open 1.75
Volume 2,248
3m Avg Volume 54,803
Today’s High 1.77
Today’s Low 1.75
52 Week High 2.85
52 Week Low 1.17
Shares Outstanding (mil) 62.39
Market Capitalization (mil) 112.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, EUR)
FY18
1
FY17
2
FY16
6
FY15
8
EPS (EUR)
FY18
-0.150
FY17
-0.692
FY16
-0.967
FY15
-0.685
*Note: Units in Millions of Euro
**Note: Units in Euro

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.15
Price to Sales (TTM)
vs sector
44.85
8.04
Price to Book (MRQ)
vs sector
1.72
4.28
Price to Cash Flow (TTM)
vs sector
--
22.37
Total Debt to Equity (MRQ)
vs sector
12.10
17.43
LT Debt to Equity (MRQ)
vs sector
6.42
13.25
Return on Investment (TTM)
vs sector
-56.47
13.23
Return on Equity (TTM)
vs sector
-60.23
15.27

EXECUTIVE LEADERSHIP

Thomas Hecht
Chairman of the Supervisory Board, Since 2007
Salary: --
Bonus: --
Adi Hoess
Chief Executive Officer, Member of the Management Board, Since 2011
Salary: --
Bonus: --
Florian Fischer
Chief Financial Officer, Member of the Management Board, Since
Salary: --
Bonus: --
Wolfgang Fischer
Chief Operating Officer, Member of the Management Board, Since 2018
Salary: --
Bonus: --
Martin Treder
Chief Scientific Officer, Member of the Management Board, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

Im Neuenheimer Feld 582
HEIDELBERG     69120

Phone: +496221.653070

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

SPONSORED STORIES